

# Peter M Voorhees

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9606522/publications.pdf>

Version: 2024-02-01

14  
papers

1,863  
citations

1163117

8  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

2671  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. <i>Cancer Medicine</i> , 2021, 10, 6933-6936.	2.8	9
2	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	4.1	15
3	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	1.4	347
4	Corrigendum to "Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays" [Thromb. Res. 139 (2016) 90-97]. <i>Thrombosis Research</i> , 2016, 147, 63.	1.7	0
5	Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays. <i>Thrombosis Research</i> , 2016, 139, 90-97.	1.7	70
6	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1551-1560.	13.7	724
7	Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius). <i>Blood</i> , 2015, 126, 1829-1829.	1.4	11
8	Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab. <i>Blood</i> , 2015, 126, 3571-3571.	1.4	8
9	Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective. <i>Blood</i> , 2015, 126, 4254-4254.	1.4	2
10	Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 6469-6478.	7.0	112
11	Emerging Data on the Use of Anthracyclines in Combination with Bortezomib in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S156-S162.	1.4	8
12	Emerging Role of Novel Combinations for Induction Therapy in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 33-41.	1.4	7
13	THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY. <i>Annual Review of Pharmacology and Toxicology</i> , 2006, 46, 189-213.	9.4	251
14	The proteasome as a target for cancer therapy. <i>Clinical Cancer Research</i> , 2003, 9, 6316-25.	7.0	299